St. Jude Medical announced sales results for Q1 2013. AIMD results from their press release: “Cardiac Rhythm Management (CRM) Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $678 million for the first quarter of 2013, an 8 percent decrease compared to the first quarter of 2012. After adjusting for the
Boston Scientific reported Q4 2012 CRM sales of $457M versus $482M for Q4 2011, or a decline of 5% (4% on constant-currency basis). For the same period, neuromodulation sales grew by 14% from $91M to $104M. Worldwide CRM sales for the full 2012 year were $1,908M compared to $2,087M for 2011, or a decline of 9%
St. Jude Medical today reported sales and net earnings for the fourth quarter and year ended December 29, 2012. According to the announcement: “Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $682 million for the fourth quarter of 2012, a 6 percent decrease compared to the fourth quarter of 2011.
Boston Scientific has received CE Mark approval for increased longevity projections for the INCEPTA™, ENERGEN™, PUNCTUA™, COGNIS® and TELIGEN® implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The longevity projections are based on data submitted to the European authorities and vary for each device dependent on the model type and settings. Projected device
Today Boston Scientific reported its results for Q3 2012. For its AIMD divisions: Cardiac Rhythm Management sales dropped from $503M in Q3 of 2011 to $462M for this year (-8%), a 6% decrease on constant-currency basis. Neuromodulation sales grew by 5% from $84M to $88M.
St. Jude announced today its third quarter 2012 results. From the press release: “Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $691 million for the third quarter of 2012, an 8 percent decrease compared with the third quarter of 2011. Total CRM sales for the third quarter decreased 4 percent
Today EnteroMedics recorded revenue for the first time since it was incorporated nearly eight years ago. The company reported revenue of about $123,000 in the first quarter of the year from the sale of its Maestro RC implantable vagus nerve stimulation system for treating obesity. Revenue was generated through sales by its distribution partner in Australia.
Yesterday Boston Scientific announced financial results for the first quarter ended March 31, 2012. Sales of Cardiac Rhythm Management devices were $501M vs. $559M for Q1 a year ago, or a decrease of 10%. Sales of Neuromodulation devices increased by 8% a year ago from $77M to $84M for Q1.
St. Jude Medical today reported sales and net earnings for the first quarter ended March 31, 2012. Total CRM sales, which include ICD and pacemaker products, were $735 million for the first quarter of 2012, a 4 percent decrease compared with the first quarter of 2011. Of that total, ICD product sales were $450 million
FDA released its PMA/Supplement approvals for January. The edited version below has been edited to include only AIMDs. It is not the full list, and should be used only for general information purposes.
Boston Scientific announced the exercise of its option to acquire Cameron Health. Cameron Health developed the world’s first and only commercially-available subcutaneous implantable cardioverter defibrillator – the S-ICD® System that I blogged about a few weeks ago. The agreement calls for an upfront payment of $150 million, payable upon transaction closing, an additional potential $150
On January 17, 2012, VeriTeQ Acquisition Corporation of Delray Beach, FL announced that it acquired the VeriChip implantable RFID technology and its related Health Link personal health record from PositiveID Corporation.
The DF-4 Connector was recently introduced by a joint group of CRM companies, physicians, and regulatory agencies as a way of easing the implant of ICDs by reducing defibrillation connections from three to one and by minimizing the number of set screws. Prior to the development of the DF-4, traditional high-voltage connector systems required up to three connections.
Today Boston Scientific Corporation announced financial results for the fourth quarter and full year ended December 31, 2011. Summarizing the AIMD data: On a constant-currency basis, Q4 2011 CRM sales were $482M compared to $564M in Q4 2010, or down 15% On a constant-currency basis, 2011 CRM sales were $2,087M compared to $2,180M in Q4 2010,
St. Jude Medical today reported sales and net earnings for the fourth quarter and year ended December 31, 2011. From the press release: “Cardiac Rhythm Management Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were$728 million for the fourth quarter of 2011, a 4 percent decrease compared to the fourth quarter of 2010. After